Organigram Global Inc. (OGI) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Organigram Global Inc. (NASDAQ: OGI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.97 (+3.43% 1D, market cap $131.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OGI ranks #370 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CATX (Perspective Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M) and KZIA (Kazia Therapeutics Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $132.2M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).
For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.7M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While OGI currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($1.02) forces dealer call-delta covering toward $2.35.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Organigram Global Inc. (OGI) surged +3.43% to $0.97, trading at 9% of its 52-week range ($0.85 – $2.24). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
Key Takeaways; Cannabis Sector Aurora Cannabis Rejected Curaleaf’s $5-a-Share Takeover Bid, Despite Exploring Alternatives Cronos Group Completed €57.5 Million Acquisition of Dutch Cannabis Producer CanAdelaar Tilray Med
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OGI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OGI. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Organigram Global Inc. (OGI) ranks #370 by composite RQD confidence (45/100, grade D) and #621 by equity capitalization ($131.6M). Within this direct 5-issuer industry benchmark cohort, OGI leads on earnings valuation at N/A trailing P/E, while CATX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KZIA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with OGI at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OGI
ACTIVE
Organigram Global Inc. | D | 45/100 | — | — | — | +3.43% | $131.6M | Benchmark Subject |
| CATX Perspective Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -9.56% | $131.3M | /catx-vs-ogi → |
| KZIA Kazia Therapeutics Limited | D | 47/100 | — | — | — | -5.65% | $132.2M | /kzia-vs-ogi → |
| SPRB Spruce Biosciences Inc. | E | 34/100 | — | — | -35.0% | -3.97% | $133.3M | /sprb-vs-ogi → |
| BGM BGM Group Ltd. (Class A) | D- | 37/100 | — | 16.6% | — | 0.00% | $127.4M | /bgm-vs-ogi → |
Organigram Global Inc. (OGI) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $131.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Organigram Global Inc. (NASDAQ: OGI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.97 (+3.43% 1D, market cap $131.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, OGI ranks #370 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CATX (Perspective Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M) and KZIA (Kazia Therapeutics Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $132.2M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).
For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
OGI last traded at $0.97 (+3.43% on volume of 186,372 shares), positioning the stock -6.73% below its 50-day simple moving average ($1.04) and -18.49% below its 200-day simple moving average ($1.19). Across its 52-week range of $0.85 to $2.24, OGI sits at the 8.6% percentile with a 14-day RSI of 41.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.5% ($1.00 to $1.04).
Organigram Global Inc. (OGI) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $0.97 (+3.43% 1D, market capitalization $131.6M).
Organigram Global Inc. (OGI) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile describes a market capitalization of $0.1B. — describes its product lineup, customer base, or revenue model. Per the recent news wire, the company plans to discontinue three cannabis brands as part of a lineup trim and a global cost-saving plan.
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector reference available is Health Care / Biotechnology: Pharmaceutical Preparations. An investor should note that the cannabis-brand discontinuation items suggest product-line exposure, but the source provides no supply-chain nodes to trace its ripple effects.
Real-time company headlines, analyst actions, and sector developments for Organigram Global Inc. (OGI) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Organigram Global Inc. (OGI) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in OGI in my $100K Virtual Cash book at $0.93. Forensic balance sheet and macro-fit pillars score 13 and 15 of 20, with a Piotroski F-Score of 6 of 9 and Debt/Equity of 0.5.. Trading inside a $0.85–$2.24 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
Both sides have a point here — OGI's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Here is the bear case nobody on the bull side wants to address on OGI: Zero ROIC and zero FCF yield leave the Fundamental Cash Engine pillar at 12 of 20, with no reported financials to corroborate profitability.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: